Pharmaceutical Veterinary Drug Streptomycin Cas 57-92-1 Streptomycin
Product Description
Product Details
| Product Name |
Streptomycin |
| Appearance |
White Powder |
| CAS NO |
57-92-1 |
| MW |
581.574 |
| MY |
C21H39N7O12 |
Streptomycin is an aminoglycoside antibiotic. In 1943, Sherman A. Waksman, a Ph.D. from the University of California, Berkeley and a professor at Rutgers University, isolated from Streptomyces and became the second antibiotic produced and used clinically after penicillin. Waksman was awarded the Nobel Prize in Physiology or Medicine in 1952 for this achievement. Its special effect of anti TB bacilli has created a new era of tuberculosis treatment. From then on, there is hope for curbing the thousands of years of human life ravaged by Mycobacterium tuberculosis.
Streptomycin is an antibiotic extracted from the culture medium of Streptomyces coelicolor. Belonging to aminoglycoside alkaline compounds, it binds to the ribonucleic acid protein body of Mycobacterium tuberculosis, interfering with the protein synthesis of Mycobacterium tuberculosis, thereby killing or inhibiting the growth of Mycobacterium tuberculosis. Due to the relatively small pain response of intramuscular injection of streptomycin, it is suitable for clinical use. As long as the application target is selected appropriately and the dosage is appropriate, most patients can receive long-term injections (usually for about 2 months). So, for decades, it has been the main drug used in anti tuberculosis treatment.
Application&Function
Streptomycin is an aminoglycoside drug. Its mechanism of action is to act on ribosomes in bacteria, inhibit bacterial protein synthesis, and disrupt the integrity of bacterial cell membranes. Sensitive bacteria have an oxygen dependent antibiotic transmembrane transport system. Streptomycin can first passively diffuse through the extracellular membrane porin, and then enter the cell through this transport system, irreversibly binding to the isolated ribosomal 30S subunit, leading to the destruction of the A-site and subsequently:
1. Prevent the correct localization of aminoacyl tRNA at position A, interfere with the assembly of functional ribosomes, and inhibit the formation of 70S initiation complexes;
2. Inducing incorrect matching of tRNA and mRNA code triplets, causing the 30S subunit of the intact ribosome to misread the genetic code, resulting in abnormal and non functional protein synthesis;
3. Obstructing the binding of termination factors to A-site, preventing the release of synthesized peptide chains, and preventing the dissociation of intact 70S ribosomes;
4. Obstructing the depolymerization and assembly process of multiple ribosomes, resulting in the depletion of ribosomes in bacteria. Streptomycin has a strong antibacterial effect on Mycobacterium tuberculosis, and its minimum inhibitory concentration (MIC) is generally 0.5mg/L. Most atypical mycobacteria are resistant to streptomycin. Streptomycin has certain antibacterial activity against many gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Escherichia coli, Salmonella, Shigella, Brucella, Pasteurella, Neisseria and Neisseria gonorrhoeae. Streptomycin has poor antibacterial activity against most Gram positive cocci such as Staphylococcus aureus. Streptomycin has no antibacterial effect on Enterococcus at commonly used doses. Streptococcus, Pseudomonas aeruginosa, and anaerobic bacteria in each group are resistant to streptomycin.
Specification
Audited Supplier 
){kind=link}